• Capivasertib regimen represents potential new treatment option for advanced breast cancer

    1 month ago - By Healio

    SAN ANTONIO - The addition of capivasertib to fulvestrant significantly extended PFS among patients with hormone receptor-positive, HER2-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.
    Capivasertib - an investigational AKT inhibitor - also appeared safe and exhibited a manageable toxicity profile, findings of the randomized phase 3 CAPItello-291 trial showed.
    “AKT activation is very frequent in many hormone receptor-positive, HER2-negative advanced breast cancers through genetic alterations in the
    Read more ...

     

  • Study finds disparities in breast cancer screening, treatment access for underserved communities

    Study finds disparities in breast cancer screening, treatment access for underserved communities

    1 month ago - By News Medical

    Barriers to breast cancer screening remain despite Medicaid expansion for preventive screening tests and implementation of patient navigation programs under the Affordable Care Act, with women from underserved communities experiencing disproportionately low rates of screening mammography, according to a study that was conducted by New York Medical College School of Medicine faculty and students and recently published in BMC Women's Health.
    Read more ...

     

  • Trastuzumab deruxtecan ‘new gold standard' in second line for breast cancer subset

    Trastuzumab deruxtecan ‘new gold standard' in second line for breast cancer subset

    1 month ago - By Healio

    SAN ANTONIO - Fam-trastuzumab deruxtecan-nxki significantly extended OS compared with ado-trastuzumab emtansine among previously treated patients with HER2-positive unresectable or metastatic breast cancer, according to study results.
    The randomized phase 3 DESTINY-Breast03 trial compared the two antibody-drug conjugates for patients whose disease progressed after trastuzumab and a taxane.
    Updated findings presented at San Antonio Breast Cancer Symposium - and simultaneously published in The Lancet - showed a 36% lower risk for death with fam-trastuzumab
    Read more ...

     

  • Camizestrant extends PFS for postmenopausal women with advanced breast cancer

    Camizestrant extends PFS for postmenopausal women with advanced breast cancer

    1 month ago - By Healio

    SAN ANTONIO - Camizestrant significantly prolonged PFS compared with fulvestrant among postmenopausal women with advanced ER-positive, HER2-negative breast cancer, according to study results.
    Camizestrant - a next-generation oral selective estrogen receptor degrader - also appeared well-tolerated, findings presented at San Antonio Breast Cancer Symposium showed.
    Hormone receptor-positive, HER2-negative breast cancer often is treated with therapies that inhibit ER activity, including selective ER modulators , aromatase inhibitors and SERDs.
    However,
    Read more ...